EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
17.74
+1.02 (6.10%)
At close: Dec 5, 2025, 4:00 PM EST
17.40
-0.34 (-1.92%)
After-hours: Dec 5, 2025, 6:43 PM EST
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for EyePoint Pharmaceuticals stock have an average target of 29.6, with a low estimate of 23 and a high estimate of 39. The average target predicts an increase of 66.85% from the current stock price of 17.74.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2025.
Analyst Ratings
The average analyst rating for EyePoint Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 5 | 4 | 4 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $28 → $39 | Buy | Maintains | $28 → $39 | +119.84% | Nov 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +52.20% | Aug 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $23 | Strong Buy | Maintains | $22 → $23 | +29.65% | Aug 6, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $28 | Buy | Initiates | $28 | +57.84% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +24.01% | May 29, 2025 |
Financial Forecast
Revenue This Year
32.44M
from 43.27M
Decreased by -25.03%
Revenue Next Year
10.90M
from 32.44M
Decreased by -66.40%
EPS This Year
-3.09
from -2.32
EPS Next Year
-2.92
from -3.09
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.6M | 47.3M | ||||
| Avg | 32.4M | 10.9M | ||||
| Low | 30.2M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -13.1% | 45.6% | ||||
| Avg | -25.0% | -66.4% | ||||
| Low | -30.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.90 | -2.09 | ||||
| Avg | -3.09 | -2.92 | ||||
| Low | -3.14 | -3.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.